S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:HARP

Harpoon Therapeutics (HARP) Stock Price, News & Analysis

$22.96
+0.02 (+0.09%)
(As of 05:26 PM ET)
Today's Range
$22.95
$22.97
50-Day Range
$10.53
$22.96
52-Week Range
$3.11
$22.97
Volume
493,845 shs
Average Volume
1.37 million shs
Market Capitalization
$388.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.25

Harpoon Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
18.7% Upside
$27.25 Price Target
Short Interest
Bearish
11.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.21mentions of Harpoon Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.49) to ($4.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.69 out of 5 stars

Medical Sector

269th out of 948 stocks

Biological Products, Except Diagnostic Industry

40th out of 157 stocks


HARP stock logo

About Harpoon Therapeutics Stock (NASDAQ:HARP)

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. 

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

HARP Stock Price History

HARP Stock News Headlines

Harpoon Therapeutics' (HARP) Neutral Rating Reiterated at Citigroup
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics
Harpoon Therapeutics just downgraded at Citi, here's why
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
HARPOON THERAPEUTICS (5HTA.BE)
Harpoon Therapeutics Inc. (5HTA.SG)
Stock (HARP), Short Interest Report
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?
Merck In Talks To Acquire Harpoon Therapeutics: Reports
See More Headlines
Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2023
Today
3/04/2024
Next Earnings (Estimated)
3/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:HARP
Fax
N/A
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.25
High Stock Price Target
$40.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+18.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-67,730,000.00
Pretax Margin
-81.67%

Debt

Sales & Book Value

Annual Sales
$37.34 million
Book Value
$1.63 per share

Miscellaneous

Free Float
14,054,000
Market Cap
$388.59 million
Optionable
Optionable
Beta
2.11
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Julie M. Eastland M.B.A. (Age 60)
    President, CEO, Secretary & Director
    Comp: $910.77k
  • Dr. Luke N. Walker M.D. (Age 52)
    Chief Medical Officer
    Comp: $424.43k
  • Mr. Michael Eric Faerm (Age 57)
    Interim Chief Financial Officer
  • Dr. Chatan Charan Ph.D.
    Senior Vice President of Product Development, Technical & Manufacturing Operations
  • Mr. James B. Bucher J.D. (Age 58)
    Chief Legal Officer
  • Ms. Wendy Chang
    Chief People Officer
  • Dr. Banmeet Anand Ph.D.
    Senior Vice President of Translational Medicine
  • Mr. Haibo Wang
    Senior Vice President of Business Development














HARP Stock Analysis - Frequently Asked Questions

Should I buy or sell Harpoon Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HARP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HARP, but not buy additional shares or sell existing shares.
View HARP analyst ratings
or view top-rated stocks.

What is Harpoon Therapeutics' stock price target for 2024?

6 equities research analysts have issued 12 month price targets for Harpoon Therapeutics' shares. Their HARP share price targets range from $23.00 to $40.00. On average, they predict the company's share price to reach $27.25 in the next year. This suggests a possible upside of 18.7% from the stock's current price.
View analysts price targets for HARP
or view top-rated stocks among Wall Street analysts.

How have HARP shares performed in 2024?

Harpoon Therapeutics' stock was trading at $11.37 at the start of the year. Since then, HARP shares have increased by 101.9% and is now trading at $22.96.
View the best growth stocks for 2024 here
.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 1,160,000 shares, an increase of 111.8% from the January 31st total of 547,700 shares. Based on an average trading volume of 951,900 shares, the days-to-cover ratio is currently 1.2 days. Approximately 11.7% of the company's stock are sold short.
View Harpoon Therapeutics' Short Interest
.

When is Harpoon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our HARP earnings forecast
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.70) by $0.80. The business had revenue of $4.09 million for the quarter, compared to the consensus estimate of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%.

When did Harpoon Therapeutics' stock split?

Shares of Harpoon Therapeutics reverse split on Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include New Leaf Venture Partners L.L.C. (10.98%), Commodore Capital LP (8.86%), Franklin Resources Inc. (8.81%), Vanguard Group Inc. (5.20%), Blackstone Inc. (4.81%) and Goldman Sachs Group Inc. (0.29%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology and Ronald Hunt.
View institutional ownership trends
.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HARP) was last updated on 3/4/2024 by MarketBeat.com Staff